Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management

The combination of glucagon-like peptide-1 (GLP-1) with other gut hormones including the glucose-dependent insulinotropic polypeptide (GIP) has been explored to complement and enhance further the GLP-1 effects on glycemia and weight loss. Tirzepatide is the first dual GLP-1/GIP receptor co-agonist w...

詳細記述

書誌詳細

出版年:	Journal of Obesity & Metabolic Syndrome
主要な著者:	Rachel Sinha, Dimitris Papamargaritis, Jack A. Sargeant, Melanie J. Davies
フォーマット:	論文
言語:	英語
出版事項:	Korean Society for the Study of Obesity 2023-03-01
主題:	diabetes mellitus type 2 obesity tirzepatide glucagon-like peptide 1 gastric inhibitory polypeptide
オンライン･アクセス:	http://www.jomes.org/journal/view.html?doi=10.7570/jomes22067